Anavex Life Sciences Corp (AVXL)

[falconer66a]

More Than Anavex 2-73 In The Stable

One short but significant phrase in the announcement should be noted:

“...an increase in preclinical activities for ANAVEX®3-71 and ANAVEX®1066.”

I’ve contended for some time that back-lab work has most surely been progressing on both new indications for Anavex molecules and the working out of indications and applications for Anavex 3-71. Added here, now, is Anavex 1066.

According the company (http://www.anavex.com/pipeline/anavex-3-71/) it might be inferred that Anavex 3-71 has greater therapeutic potential for Alzheimer’s than even Anavex 2-73

Anavex 1066 (http://www.anavex.com/pipeline/anavex-1066/) targets various pains. The markets for such an application, including the very common neuropathic pains of diabetes, are very large.

Anavex 2-73 is just an early chapter of the ever-expanding Anavex story. Indications and applications will extend far beyond Rett, Alzheimer’s, and Parkinson’s.

Anavex Life Sciences Corp is not a one-trick pony. It’s an entire stable of powerful therapeutic steeds, requiring development. Such development has just been indicated for two new Anavex drugs.